A Mambie1, F Vuotto1, D Poitrenaud1, P Weyrich1, O Cannesson1, R Dessein2, K Faure3, B Guery3, T Galpérine4. 1. CHU de Lille, Maladies Infectieuses, 59000 Lille, France. 2. CHU de Lille, Bactériologie-Hygiène, 59045 Lille, France. 3. CHU de Lille, Maladies Infectieuses, 59000 Lille, France; Université de Lille, EA 7366, Recherche translationnelle, relations hôte-pathogènes, 59000 Lille, France. 4. CHU de Lille, Maladies Infectieuses, 59000 Lille, France. Electronic address: tatgalp@yahoo.com.
Abstract
BACKGROUND AND OBJECTIVES: Infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) have become a major public health issue worldwide. Cefoxitin is a second-generation cephalosporin and is associated with a strong in vitro activity against ESBL. PATIENTS AND METHODS: We conducted a prospective monocentric cohort study from 2012 to 2015 to evaluate the clinical efficacy and safety of cefoxitin in 15 patients treated for urinary tract infection (UTI) caused by ESBL-E, without any severity criteria. RESULTS: We included 15 patients; 11 were male patients with defined risk factors for ESBL-E. Ten patients presented with male UTI, three with pyelonephritis, and two with cystitis. Escherichia coli was the predominant pathogen. All patients had a positive outcome with a good tolerance (a skin rash without any sign of severity was observed in one patient). Microbiological cure was obtained in 9 patients out of 10 at the end of treatment. CONCLUSION: Cefoxitin is an alternative treatment to carbapenems for urinary tract infections caused by ESBL-producing Enterobacteriaceae.
BACKGROUND AND OBJECTIVES: Infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) have become a major public health issue worldwide. Cefoxitin is a second-generation cephalosporin and is associated with a strong in vitro activity against ESBL. PATIENTS AND METHODS: We conducted a prospective monocentric cohort study from 2012 to 2015 to evaluate the clinical efficacy and safety of cefoxitin in 15 patients treated for urinary tract infection (UTI) caused by ESBL-E, without any severity criteria. RESULTS: We included 15 patients; 11 were male patients with defined risk factors for ESBL-E. Ten patients presented with male UTI, three with pyelonephritis, and two with cystitis. Escherichia coli was the predominant pathogen. All patients had a positive outcome with a good tolerance (a skin rash without any sign of severity was observed in one patient). Microbiological cure was obtained in 9 patients out of 10 at the end of treatment. CONCLUSION:Cefoxitin is an alternative treatment to carbapenems for urinary tract infections caused by ESBL-producing Enterobacteriaceae.
Authors: O Senard; M Lafaurie; P Lesprit; Y Nguyen; X Lescure; A Therby; V Fihman; N Oubaya; R Lepeule Journal: Eur J Clin Microbiol Infect Dis Date: 2019-09-11 Impact factor: 3.267
Authors: Wasim S El Nekidy; Manal M Abdelsalam; Ahmad R Nusair; Rania El Lababidi; Ruba Z Dajani; Terrence J Lee St John; Islam M Ghazi Journal: Hosp Pharm Date: 2021-12-30